Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02

What Was Tested

Researchers studied Goserelin in this randomized controlled trial publication.

Radiation Therapy Oncology Group (RTOG) Protocol 92-02 was a randomized trial testing long-term (LT) adjuvant androgen deprivation (AD) after initial AD with external-beam radiotherapy (RT) in patients with locally advanced prostate cancer (PC; T2c-4) and with prostate-specific antigen level less than 150 ng/mL.

Who Took Part

The abstract describes 1,554 patients taking part.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, men only.

Patients received a total of 4 months of goserelin and flutamide, 2 months before and 2 months during RT.

Patients were randomly assigned to receive no additional therapy (short-term [ST]AD-RT) or 24 months of goserelin (LTAD-RT); 1,554 patients were entered onto the study.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Goserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Adenocarcinoma, Androgen Antagonists, Antineoplastic Agents, Hormonal, Chemotherapy, Adjuvant, Combined Modality Therapy, Disease-Free Survival and Goserelin.

What This Means in Plain Language

The paper is a randomized study of Goserelin in 1,554 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Goserelin compound page.